Long-lasting radionuclide therapy for advanced neuroendocrine tumors proves effective

(Society of Nuclear Medicine and Molecular Imaging) A first-in-human study presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates the benefits and safety of a new, long-lasting type of radionuclide therapy for patients with advanced, metastatic neuroendocrine tumors (NETs).

https://www.eurekalert.org/pub_releases/2018-06/sonm-lrt062518.php

Source: EurekAlert! - Cancer - June 25, 2018 Category: Cancer & Oncology Source Type: news